Molecular Partners AG Files Routine 6-K Disclosure
Ticker: MOLN · Form: 6-K · Filed: Jan 13, 2025 · CIK: 1745114
Sentiment: neutral
Topics: disclosure, foreign-private-issuer, routine-filing
TL;DR
Molecular Partners AG filed a 6-K, just a routine check-in, no big news.
AI Summary
Molecular Partners AG filed a Form 6-K on January 13, 2025, to report its status as a foreign private issuer. The company, incorporated in Switzerland, is required to file annual reports under Form 20-F. This filing does not contain specific financial updates or material events but serves as a routine disclosure.
Why It Matters
This filing is a standard procedural document for foreign private issuers, indicating no new material information has been released by Molecular Partners AG at this time.
Risk Assessment
Risk Level: low — This filing is a standard procedural disclosure for a foreign private issuer and does not contain new material information.
Key Players & Entities
- Molecular Partners AG (company) — Registrant
- 001-40488 (company) — SEC File Number
- 20250113 (date) — Filing Date
- 20250112 (date) — Period of Report
FAQ
What is the purpose of this Form 6-K filing by Molecular Partners AG?
The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of January 2025.
When was this Form 6-K filed?
This Form 6-K was filed on January 13, 2025.
Does Molecular Partners AG file annual reports under Form 20-F or 40-F?
Molecular Partners AG indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address of Molecular Partners AG?
The principal executive office is located at Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland.
What is the SEC file number for Molecular Partners AG?
The SEC file number for Molecular Partners AG is 001-40488.
Filing Stats: 170 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2025-01-13 17:13:45
Filing Documents
- f6k_011325.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 15KB
- 0001171843-25-000212.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Molecular Partners AG (Registrant) Date: January 12, 2025 /s/ PATRICK AMSTUTZ Patrick Amstutz Chief Executive Officer